Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients

Background Kidney dysfunction is linked to nonalcoholic fatty liver disease (NAFLD) progression including fibrosis, steatosis, or inflammation. We aimed to explore whether lower levels of estimated glomerular filtration rate (eGFR) was associated with increased probability of liver fibrosis. Methods...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes/metabolism research and reviews 2020-07, Vol.36 (5), p.e3294-n/a
Hauptverfasser: Wang, Yuying, Yu, Yuetian, Wan, Heng, Chen, Yi, Xia, Fangzhen, Zhang, Wen, Zhang, Kun, Gu, Xinjie, Zhang, Yihao, Lin, Zhiqi, Yu, Yuefeng, Wang, Ningjian, Lu, Yingli
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Kidney dysfunction is linked to nonalcoholic fatty liver disease (NAFLD) progression including fibrosis, steatosis, or inflammation. We aimed to explore whether lower levels of estimated glomerular filtration rate (eGFR) was associated with increased probability of liver fibrosis. Methods Two thousand six hundred eighty‐nine subjects enrolled from Shanghai, China, were included in this study. NAFLD fibrosis score (NFS) was used to risk stratify NAFLD patients for fibrosis. eGFR was used to assess kidney function. The association of eGFR level with elevated NFS, and thus high risk of fibrosis, was analysed by linear regression and multinomial logistic regression. The predictive power of eGFR was evaluated via receiver operating characteristic (ROC) curve. Results A negative association was found between eGFR and NFS (B = −0.21, 95% CI, −0.37 to −0.04, P = .016). As eGFR quartiles decreased, the prevalence of probable fibrosis increased after adjusting for age, sex, current smoking, waist circumference, duration of diabetes, HbA1c, hypertension, dyslipidaemia, and homeostasis model assessment index of insulin resistance (HOMA‐IR) (Q4: reference; Q3: 1.49, 95% CI, 0.82‐2.71; Q2: 1.88, 95% CI, 0.97‐3.67; Q1: 2.70, 95% CI, 1.36‐5.37, Pfor trend = .002, 1SD increment: 0.73, 95% CI, 0.58‐0.92). The eGFR level can be an effective indicator in differentiating patients with probable presence of fibrosis from those without (AUROC: 0.71, cut‐off point: 92.78 mL/min/1.73 m2, P 
ISSN:1520-7552
1520-7560
DOI:10.1002/dmrr.3294